NDAORALTABLETPriority Review
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SYMFI (efavirenz, lamivudine and tenofovir disoproxil fumarate) by Viatris (2) is non-nucleoside reverse transcriptase inhibitors [moa]. First approved in 2018.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMFI is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate for the treatment of HIV-1 infection. It works by inhibiting reverse transcriptase, a key enzyme required for HIV replication. This oral combination therapy simplifies dosing for HIV patients by combining three antiretroviral agents into a single tablet.
$0.001BPart D
PeakSYMFI is at peak lifecycle maturity with modest Part D utilization (377 claims, $1M spending in 2023), indicating a stable but smaller market footprint appropriate for focused commercial teams.
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYMFI careers focus on commercial execution within a mature, stable HIV treatment franchise under Viatris ownership. Roles emphasize market access, cost-effectiveness positioning, and physician engagement in a competitive landscape with modest growth prospects.
Brand Manager
Worked on SYMFI at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.